Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
Respir Med
; 107(5): 768-77, 2013 May.
Article
em En
| MEDLINE
| ID: mdl-23490222
ABSTRACT
OBJECTIVES:
To assess the cost-effectiveness ratio of rifampin for 4 months and isoniazid for 6 months in contacts with latent tuberculosis infection.METHODS:
The cost was the sum of the cost of treatment with isoniazid for 6 months or with rifampin for 4 months of all contacts plus the cost of treatment of cases of tuberculosis not avoided. The effectiveness was the number of cases of tuberculosis avoided with isoniazid for 6 months or with rifampin for 4 months. When the cost with one schedule was found to be cheaper than the other and a greater number of tuberculosis cases were avoided, this schedule was considered dominant. The efficacy adopted was 90% for rifampin for 4 months and 69% for isoniazid for 6 months. A sensitivity analysis was made for efficacies of rifampin for 4 months of 80%, 69%, 60% and 50%.RESULTS:
Of the 1002 patients studied, 863 were treated with isoniazid for 6 months and 139 with rifampin for 4 months The cost-effectiveness ratio with isoniazid for 6 month was 19759.48/avoided case of tuberculosis and 8736.86/avoided case of tuberculosis with rifampin for 4 months. Rifampin for 4 months was dominant. In the sensitivity analysis, rifampin for 4 months was dominant for efficacies from 60%.CONCLUSIONS:
Rifampin for 4 months was more cost-effective than isoniazid for 6 months.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Rifampina
/
Custos de Medicamentos
/
Tuberculose Latente
/
Isoniazida
/
Antituberculosos
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Health_economic_evaluation
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article